Review the latest data and expert guidance on PARP inhibitors to enhance your treatment of ovarian cancer. This comprehensive CME/CE/CPE-certified program features decision support tools, focused commentaries, an expert analysis module, and a downloadable slideset.
Have you fully integrated the PARP inhibitors—olaparib, niraparib, and rucaparib—into your clinical practice in ovarian cancer? In this commentary, I discuss the importance of PARP inhibitors in ovarian cancer treatment and review considerations guiding their use.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.